Biologics Cut Heart Disease Risk by 38% in Psoriasis Patients vs Oral Drugs
Large study of 25,000+ patients shows biologic therapies significantly reduce cardiovascular events compared to traditional oral treatments.
Summary
A major study analyzing over 25,000 psoriasis patients found that those treated with biologic drugs had a 38% lower risk of cardiovascular disease compared to patients on oral medications. The five-year analysis showed biologics targeting TNF-α, IL-17, and IL-23 provided significant heart protection, while IL-12/23 inhibitors showed no benefit. This suggests inflammation-targeting biologics may offer cardiovascular benefits beyond skin improvement in psoriasis patients.
Detailed Summary
Psoriasis patients face elevated cardiovascular disease risk due to chronic systemic inflammation. This comprehensive study examined whether advanced biologic therapies could reduce this risk compared to traditional oral treatments.
Researchers analyzed data from the TriNetX Global Network covering 156 million patients across 18 countries from 2014-2025. They compared 12,732 psoriasis patients newly prescribed biologics against 12,732 matched patients on oral anti-psoriatic drugs, controlling for age, sex, race, comorbidities, BMI, lipid profiles, and inflammatory markers.
The results were striking: patients on biologics showed a 38% lower risk of developing any cardiovascular disease over five years (10.68% vs 16.17% cumulative incidence). The protection extended across multiple conditions including stroke (38% reduction), heart failure (36% reduction), and major cardiac events (30% reduction). Notably, biologics targeting TNF-α, IL-17, and IL-23 individually showed significant benefits, while IL-12/23 inhibitors did not.
These findings suggest that biologics' anti-inflammatory effects may provide cardiovascular protection beyond their skin benefits. The consistency across different patient subgroups and eight sensitivity analyses strengthens the evidence. However, this observational study cannot prove causation, and the mechanisms behind differential biologic effects remain unclear.
For clinicians, these results support considering cardiovascular benefits when selecting psoriasis treatments, particularly for high-risk patients. The data may influence treatment guidelines and insurance coverage decisions for biologic therapies in psoriasis management.
Key Findings
- Biologics reduced overall cardiovascular disease risk by 38% vs oral treatments
- Five-year CVD incidence: 10.68% with biologics vs 16.17% with oral drugs
- TNF-α, IL-17, and IL-23 inhibitors showed protection; IL-12/23 did not
- Benefits consistent across stroke, heart failure, and major cardiac events
- Risk reduction maintained across age groups, sexes, and comorbidity profiles
Methodology
Retrospective cohort study using TriNetX Global Network data (2014-2025) with propensity score matching of 12,732 patients per group. Five-year follow-up with Cox regression analysis and eight sensitivity analyses to validate findings.
Study Limitations
Observational design cannot establish causation. Potential confounding from disease severity differences between treatment groups. Limited long-term safety data and mechanistic understanding of differential biologic effects on cardiovascular outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.